{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T19:28:29Z","timestamp":1777577309112,"version":"3.51.4"},"reference-count":49,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T00:00:00Z","timestamp":1602460800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["P50HD090254"],"award-info":[{"award-number":["P50HD090254"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-16-1-0557"],"award-info":[{"award-number":["W81XWH-16-1-0557"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>Prednisone (Pred) and Deflazacort (Dfz) are commonly used glucocorticoids (GCs) for Duchenne muscular dystrophy (DMD) treatment and management. While GCs are known to delay the loss of ambulation and motor abilities, chronic use can result in onerous side effects, e.g., weight gain, growth stunting, loss of bone density, etc. Here, we use the CINRG Duchenne natural history study to gain insight into comparative safety of Pred versus Dfz treatment through GC-responsive pharmacodynamic (PD) biomarkers. Longitudinal trajectories of SOMAscan\u00ae protein data obtained on serum of DMD boys aged 4 to 10 (Pred: n = 7; Dfz: n = 8) were analyzed after accounting for age and time on treatment. Out of the pre-specified biomarkers, seventeen candidate proteins were differentially altered between the two drugs (p &lt; 0.05). These include IGFBP-2 and AGER associated with diabetes complications, and MMP-3 associated with extracellular remodeling. As a follow-up, IGFBP-2, MMP-3, and IGF-I were quantified with an ELISA using a larger sample size of DMD biosamples (Dfz: n = 17, Pred: n = 12; up to 76 sera samples) over a longer treatment duration. MMP-3 and IGFBP-2 validated the SOMAscan\u00ae signal, however, IGF-I did not. This study identified GC-responsive biomarkers, some associated with safety, that highlight differential PD response between Dfz and Pred.<\/jats:p>","DOI":"10.3390\/jpm10040164","type":"journal-article","created":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T09:22:43Z","timestamp":1602580963000},"page":"164","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Comparison of Serum Pharmacodynamic Biomarkers in Prednisone-Versus Deflazacort-Treated Duchenne Muscular Dystrophy Boys"],"prefix":"10.3390","volume":"10","author":[{"given":"Shefa","family":"Tawalbeh","sequence":"first","affiliation":[{"name":"Department of Biomedical Engineering, Binghamton University, Binghamton, NY 13902, USA"},{"name":"Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, Binghamton University, Binghamton, NY 13902, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison","family":"Samsel","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, Binghamton University, Binghamton, NY 13902, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather","family":"Gordish-Dressman","sequence":"additional","affiliation":[{"name":"Division of Biostatistics, Children\u2019s National Hospital, Washington, DC 20010, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yetrib","family":"Hathout","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, Binghamton University, Binghamton, NY 13902, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"CINRG-DNHS Investigators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Utkarsh J.","family":"Dang","sequence":"additional","affiliation":[{"name":"Department of Health Outcomes and Administrative Sciences, School of Pharmacy and Pharmaceutical Sciences, Binghamton University, Binghamton, NY 13902, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,10,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/0092-8674(87)90579-4","article-title":"Dystrophin: The protein product of the Duchenne muscular dystrophy locus","volume":"51","author":"Hoffman","year":"1987","journal-title":"Cell"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1146\/annurev.physiol.010908.163216","article-title":"Mechanisms of muscle degeneration, regeneration, and repair in the muscular dystrophies","volume":"71","author":"Wallace","year":"2009","journal-title":"Annu. Rev. Physiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1007\/s40265-014-0287-4","article-title":"Ataluren: First global approval","volume":"74","author":"Ryan","year":"2014","journal-title":"Drugs"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/ana.23982","article-title":"Eteplirsen for the treatment of Duchenne muscular dystrophy","volume":"74","author":"Mendell","year":"2013","journal-title":"Ann. Neurol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1007\/s40265-016-0657-1","article-title":"Eteplirsen: First global approval","volume":"76","author":"Syed","year":"2016","journal-title":"Drugs"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s40265-020-01267-2","article-title":"Golodirsen: First approval","volume":"80","author":"Heo","year":"2020","journal-title":"Drugs"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e2270","DOI":"10.1212\/WNL.0000000000009233","article-title":"Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy","volume":"94","author":"Frank","year":"2020","journal-title":"Neurology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ajpath.2011.03.050","article-title":"Restoring dystrophin expression in Duchenne muscular dystrophy muscle: Progress in exon skipping and stop codon read through","volume":"179","author":"Hoffman","year":"2011","journal-title":"Am. J. Pathol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1474-4422(09)70271-6","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 1: Diagnosis, and pharmacological and psychosocial management","volume":"9","author":"Bushby","year":"2010","journal-title":"Lancet Neurol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1212\/WNL.0000000000003217","article-title":"Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy","volume":"87","author":"Griggs","year":"2016","journal-title":"Neurology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(17)32160-8","article-title":"Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: A prospective cohort study","volume":"391","author":"McDonald","year":"2018","journal-title":"Lancet"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1212\/WNL.0000000000001950","article-title":"Prednisone\/prednisolone and deflazacort regimens in the CINRG Duchenne Natural History Study","volume":"85","author":"Bello","year":"2015","journal-title":"Neurology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jpeds.2016.02.067","article-title":"Corticosteroid treatment and growth patterns in ambulatory males with Duchenne muscular dystrophy","volume":"173","author":"Lamb","year":"2016","journal-title":"J. Pediatr."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1002\/1097-4598(200009)23:9<1344::AID-MUS4>3.0.CO;2-F","article-title":"A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy","volume":"23","author":"Bonifati","year":"2000","journal-title":"Muscle Nerve"},{"key":"ref_15","first-page":"529","article-title":"Variable effects of corticosteroid treatment of serum enzyme activities in Duchenne\u2019s muscular dystrophy","volume":"17","author":"Cohen","year":"1977","journal-title":"Res. Commun. Chem. Pathol. Pharmacol."},{"key":"ref_16","unstructured":"(2020, September 01). FDA News Release (2017) FDA Approves Drug to Treat Duchenne Muscular Dystrophy, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-drug-treat-duchenne-muscular-dystrophy."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"12167","DOI":"10.1038\/s41598-019-48548-9","article-title":"Disease-specific and glucocorticoid-responsive serum biomarkers for Duchenne muscular dystrophy","volume":"9","author":"Hathout","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1093\/hmg\/ddaa132","article-title":"Serum biomarkers associated with baseline clinical severity in young steroid-na\u00efve Duchenne muscular dystrophy boys","volume":"29","author":"Dang","year":"2020","journal-title":"Hum. Mol. Genet."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/jcsm.12304","article-title":"Tracking disease progression non-invasively in Duchenne and Becker muscular dystrophies","volume":"9","author":"Spitali","year":"2018","journal-title":"J. Cachexia. Sarcopenia Muscle"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1046\/j.1365-2265.2002.01580.x","article-title":"Short-term effects on linear growth and bone turnover in children randomized to receive prednisolone or dexamethasone","volume":"57","author":"Ahmed","year":"2002","journal-title":"Clin. Endocrinol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Matthews, E., Brassington, R., Kuntzer, T., Jichi, F., and Manzur, A.Y. (2016). Corticosteroids for the treatment of Duchenne muscular dystrophy. Cochrane Database Syst. Rev.","DOI":"10.1002\/14651858.CD003725.pub4"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/mus.26736","article-title":"Deflazacort vs prednisone treatment for Duchenne muscular dystrophy: A meta-analysis of disease progression rates in recent multicenter clinical trials","volume":"61","author":"McDonald","year":"2020","journal-title":"Muscle Nerve."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1177\/0961203317751854","article-title":"Head to head comparison of adverse effects and efficacy between high dose deflazacort and high dose prednisolone in systemic lupus erythematosus: A prospective cohort study","volume":"27","author":"Ganapati","year":"2018","journal-title":"Lupus"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"31727","DOI":"10.1038\/srep31727","article-title":"Serum pharmacodynamic biomarkers for chronic corticosteroid treatment of children","volume":"6","author":"Hathout","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.steroids.2018.10.008","article-title":"Serum biomarkers of glucocorticoid response and safety in anti-neutrophil cytoplasmic antibody-associated vasculitis and juvenile dermatomyositis","volume":"140","author":"Conklin","year":"2018","journal-title":"Steroids"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/mus.23807","article-title":"The cooperative international neuromuscular research group duchenne natural history study-a longitudinal investigation in the era of glucocorticoid therapy: Design of protocol and the methods used","volume":"48","author":"McDonald","year":"2013","journal-title":"Muscle Nerve"},{"key":"ref_27","unstructured":"R Core Team (2019). R: A Language and Environment for Statistical Computing, R Foundation for Statistical Computing."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v067.i01","article-title":"Fitting linear mixed-effects models using lme4","volume":"67","author":"Bates","year":"2015","journal-title":"J. Stat. Softw."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v082.i13","article-title":"lmerTest package: Tests in linear mixed effects models","volume":"82","author":"Kuznetsova","year":"2017","journal-title":"J. Stat. Softw."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nm1217","article-title":"Kielin\/chordin-like protein, a novel enhancer of BMP signaling, attenuates renal fibrotic disease","volume":"11","author":"Lin","year":"2005","journal-title":"Nat. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.pharep.2016.03.006","article-title":"Is insulin-like growth factor 1 (IGF-1) system an attractive target inflammatory bowel diseases? Benefits and limitation of potential therapy","volume":"68","author":"Zatorski","year":"2016","journal-title":"Pharmacol. Rep."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.semcdb.2016.09.013","article-title":"Fibrosis development in early-onset muscular dystrophies: Mechanisms and translational implications","volume":"64","author":"Serrano","year":"2017","journal-title":"Semin. Cell Dev. Biol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.2337\/db12-1528","article-title":"SRAGE and risk of diabetes, cardiovascular disease, and death","volume":"62","author":"Selvin","year":"2013","journal-title":"Diabetes"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"8776","DOI":"10.3748\/wjg.v21.i29.8776","article-title":"Advances in refractory ulcerative colitis treatment: A new therapeutic target, Annexin A2","volume":"21","author":"Tanida","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Liu, N., Jiang, Y., Chung, J.Y., Li, Y., Yu, Z., Kim, J.W., Lok, J.M., Whalen, M.J., and Wang, X. (2019). Annexin A2 deficiency exacerbates neuroinflammation and long-term neurological deficits after traumatic brain injury in mice. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20246125"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1093\/hmg\/ddx065","article-title":"Annexin A2 links poor myofiber repair with inflammation and adipogenic replacement of the injured muscle","volume":"26","author":"Defour","year":"2017","journal-title":"Hum. Mol. Genet."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1111\/apt.13801","article-title":"Single-centre experience of the macrophage activation marker soluble (s)CD163\u2013associations with disease activity and treatment response in patients with autoimmune hepatitis","volume":"44","author":"Kreutzfeldt","year":"2016","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1159\/000439052","article-title":"Glucocorticoid-induced leucine zipper is expressed in human neutrophils and promotes apoptosis through Mcl-1 down-regulation","volume":"8","author":"Espinasse","year":"2016","journal-title":"J. Innate Immun."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1002\/jcb.24621","article-title":"GPNMB enhances bone regeneration by promoting angiogenesis and osteogenesis: Potential role for tissue engineering bone","volume":"114","author":"Hu","year":"2013","journal-title":"J. Cell. Biochem."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1080\/14728222.2016.1212018","article-title":"Prospects of osteoactivin in tissue regeneration","volume":"20","author":"Huang","year":"2016","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Belongie, K.J., Ferrannini, E., Johnson, K., Andrade-Gordon, P., Hansen, M.K., and Petrie, J.R. (2017). Identification of novel biomarkers to monitor \u03b2-cell function and enable early detection of type 2 diabetes risk. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0182932"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1210\/en.2007-1068","article-title":"Gender-specific changes in bone turnover and skeletal architecture in Igfbp-2-null mice","volume":"149","author":"DeMambro","year":"2008","journal-title":"Endocrinology"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.4049\/jimmunol.124.6.2812","article-title":"Immunosuppressive effects of low doses of glucocorticoids: Effects on autologous and allogeneic mixed leukocyte reactions","volume":"124","author":"Hahn","year":"1980","journal-title":"J. Immunol."},{"key":"ref_44","first-page":"3795","article-title":"Effects of deflazacort versus prednisone on bone mass, body composition, and lipid profile: A randomized, double blind study in kidney transplant patients","volume":"83","author":"Lippuner","year":"1998","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/BF00542555","article-title":"Acute effect of prednisone and deflazacort on glucose tolerance in prediabetic subjects","volume":"22","author":"Pagano","year":"1982","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e156","DOI":"10.1038\/mtna.2014.7","article-title":"Targeting TGF-\u03b2 signaling by antisense oligonucleotide-mediated knockdown of TGF-\u03b2 type I receptor","volume":"3","author":"Kemaladewi","year":"2014","journal-title":"Mol. Ther.-Nucleic Acids"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1001\/jamaneurol.2019.0242","article-title":"Fractures and linear growth in a nationwide cohort of boys with Duchenne muscular dystrophy with and without glucocorticoid treatment: Results from the UK Northstar database","volume":"76","author":"Joseph","year":"2019","journal-title":"JAMA Neurol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2217\/cer-2019-0170","article-title":"Real-world outcomes of long-term prednisone and deflazacort use in patients with Duchenne muscular dystrophy: Experience at a single, large care center","volume":"9","author":"Marden","year":"2020","journal-title":"J. Comp. Eff. Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.phrs.2018.09.007","article-title":"Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug","volume":"136","author":"Conklin","year":"2018","journal-title":"Pharmacol. Res."}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/10\/4\/164\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:19:50Z","timestamp":1760177990000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/10\/4\/164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,12]]},"references-count":49,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["jpm10040164"],"URL":"https:\/\/doi.org\/10.3390\/jpm10040164","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,12]]}}}